Listing 1 - 10 of 68 | << page >> |
Sort by
|
Choose an application
Japan --- Japanse binding --- Fotografie --- Esthetica --- Keramiek --- Papier
Choose an application
Cell receptors. --- Cell receptors --- Physiological effect. --- Cell membrane receptors --- Cell surface receptors --- Receptors, Cell --- Binding sites (Biochemistry) --- Cell membranes --- Proteins
Choose an application
Lymphangiogenesis consists in the formation of new lymphatic vessels from already established ones. This complex biological process is triggered during inflammation, wound repair or cancer. A decrease or defect in lymphangiogenesis leads to a pathology called lymphedema. This condition is characterised by tissue swelling caused by the accumulation of interstitial fluids. Nowadays there is no curative therapy. Vascular Endothelial Growth Factor Receptors 2 and 3 (VEGFR 2/3) represent interesting therapeutic targets as they are known to be major lymphangiogenesis inducers. Previous work from the host laboratory has identified the endocytic receptor “urokinase plasminogen activator receptor-associated protein” (“uPARAP” encoded by MRC2 gene) as negatively regulating lymphangiogenesis. uPARAP interacts with VEGFR 2/3 and blocks their heterodimerisation and signalisation. More recently, the laboratory has identified the interaction of uPARAP with Vascular Endothelial cadherin (VE-cadherin), a transmembrane protein also known to play key roles in lymphangiogenesis. The aim of this work is to identify the binding site between uPARAP and VE-cadherin or VEGFR 2/3 in order to provide better knowledge on uPARAP’s functions in lymphatics. A collaboration with Pr. Miikka Vikkula (UCL) had previously identified 7 uPARAP variants from a primary lymphedema patient cohort. We generated and validated upon this work multiple engineered A431 cell lines to express some known uPARAP partners (VE- cadherin, VEGF-R2 and VEGF-R3). Through proximity ligation assays, we successfully identified two variants (Thr653Met, Arg680Trp) who decreased uPARAP interactions with VE- cadherin. Finally, we tried but failed to produce new lentiviral vectors containing the previously identified variants. Those vectors were though to permit the investigation of variant impacts in primary human lymphatic endothelial cells Le processus de génération de nouveaux vaisseaux sanguins à partir de vaisseaux préexistants est appelé ‘’lymphangiogenèse’’. Ce processus biologique complexe est déclenché pendant l’inflammation, lors des processus de réparation des tissus ou boen encore lors de cancers. Une diminution ou un défaut de lymphangiogenèse mène au développement d’une pathologie appelée ‘’lymphoedème’’. Cette pathologie est chartérisée par le gonflement des tissus causé par une accumulation de fluides au sein des tissus. Aucune thérapie n’existe actuellement pour soigner définitivement cette pathologie. Les récepteurs aux facteurs de croissance vasculaire endothélial (vascular endothelial growth factor receptors -VEGFRs-) de type 2 et 3 (VEGF-R2 et VEGF-R3) forment des cibles thérapeutiques intéressantes de par leurs rôles majeurs dans l’induction et la régulation de la lymphangiogenèse. De précédent travaux au sein du laboratoire d’accueil ont identifié le récepteur endocytique ‘’urokinase plasminogen activator receptor-associated protein’’ (uPARAP, produit de l’expression du gene MRC2) comme régulant négativement la lymphangiogenèse. uPARAP inhibe la formation d’hétérodimeres VEGF-R2/VEGF-R3 et bloque ainsi leur signalisation. Plus récemment, le laboratoire d’accueil a identifié l’interaction d’uPARAP avec la vascular endothelial cadherin (VE-cadherin), une protein transmembranaire également connue dans la lymphangiogenèse. Le but de ce travail est d’identifier le ou les site(s) de liaison d’uPARAP avec ses différents partenaires (VE-cadherin ou VEGF-R2/R3) afin d’obtenir une plus profonde connaissance des fonctions d’uPARAP dans le système lymphatique. En collaboration avec le Professeur Miikka Vikkula (UCL), 7 variants ont précédemment été identifiés. Au cours de ce travail, nous avons induit et validé l’expression de la VE-cadherin at des VEGF-R2 et R3 dans une lignée de cellules cancéreuses (A431). Nous avons ensuite identifié avec succès deux variants (Thr653Met, Arg680Trp) diminuant l’interaction d’uPARAP avec la VE-cadherin. Enfin, nous avons essayé mais échoué à produire de nouveau vecteurs lentiviraux contenant les différents variants. Ces vecteurs étaient destinés à l’évaluation de l’impact des variants au sein de cellules endothéliales lymphatiques humaines.
Lymphangiogenesis --- uPARAP --- VE-cadherin --- VEGF-R2 --- VEGF-R3 --- Binding site --- Sciences du vivant > Biochimie, biophysique & biologie moléculaire
Choose an application
"Allosteric Modulation of G Protein-Coupled Receptors reviews fundamental information on G protein-coupled receptors (GPCRs) and allosteric modulation, presenting original research in the area and collectively providing a comprehensive description of key issues in GPCR allosteric modulation. The book provides background on core concepts of molecular pharmacology while also introducing the most important advances and studies in the area. It also discusses key methodologies."--
Allosteric regulation. --- Allosteric mechanisms --- Allosteric modulation --- Allosterism --- Mechanisms, Allosteric --- Modulation, Allosteric --- Regulation, Allosteric --- Biological control systems --- G proteins --- GTP-Binding Proteins --- Allosteric Regulation --- Receptors.
Choose an application
"Since their discovery and subsequent development into laboratory tools, CRISPR Cas systems have revolutionized the science of gene editing and their possible applications continue to expand, from basic research to potentially groundbreaking medical and commercial uses. Led by a distinguished team of editors, CRISPR Biology and Applications explores the subject matter needed to delve into this fascinating area. This comprehensive text presents the diversity of CRISPR Cas systems, the underlying biology of these systems, and CRISPR based technologies and applications".
CRISPR (génétique). --- Génétique microbienne. --- Protéines de liaison à l'ARN. --- Microbial genetics. --- CRISPR-Cas Systems. --- Genetics, Microbial. --- RNA-Binding Proteins. --- Microbial genetics.
Choose an application
La première histoire des couvertures de livres en langue française, riche de plus de 200 illustrations. Cette « histoire visuelle » explore les modalités et la finalité de la conception éditoriale, matérielle et graphique des couvertures de livres publiés dans toute l’Europe, dans les pays anglo-saxons, sans oublier les spécificités des productions nées dans les pays de l’Est comme en Asie.
655.534 --- 76 <09> --- 76 <09> Geschiedenis van de grafische kunsten --- Geschiedenis van de grafische kunsten --- 655.534 Binding, casing, book cover --- 655.534 Stofomslag. Cover. Boekomslag --- Binding, casing, book cover --- Stofomslag. Cover. Boekomslag --- Livres --- Édition. --- Arts graphiques. --- Couvertures. --- Book history --- bindings [gathered matter components] --- Book cover art --- Book cover art. --- History. --- Book covers --- Graphic design (Typography) --- Publishers and publishing. --- bookbinding [process]
Choose an application
Antiphospholipid syndrome. --- Immunologic diseases. --- Phospholipid antibodies. --- Anti-phospholipid antibodies --- Antibodies against phospholipids --- Antiphospholipid antibodies --- Phospholipid-binding antibodies --- Autoantibodies --- Immune diseases --- Immune disorders --- Immune system --- Immunologic disorders --- Immunological diseases --- Diseases --- Hughes syndrome --- Sticky blood syndrome --- Autoimmune diseases --- Syndromes
Choose an application
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies
Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier
Choose an application
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies
interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier
Choose an application
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies
Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood-brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood-brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker
Listing 1 - 10 of 68 | << page >> |
Sort by
|